BUSINESS
Aranesp, according to the investment firm Friedman Billings Ramsey. This month, a Food & Drug Administration committee recommended further narrowing the use of Aranesp and Procrit. The Oncology Drug Advisory Committee did not offer specific targets, but it said the drugs should be given only to patients with hemoglobin levels that fall below a certain
A STEADY START Bigbiotech firms offer STABLE RESULTS despite maturing portfolios LISA M. JARVIS, C&EN NORTHEAST NEWS BUREAU
THE BIG BIOTECHNOLOGY companies
that now rival big pharmaceutical makers in size also experienced big-pharma-sized challenges in the first quarter. Although financial results are steady for these firms, their product portfolios have matured, thereby hampering their ability to achieve the dynamic sales growth they boasted just two or three years ago. The bigger challenges are that the safety of certain key products is under a cloud and that the pipeline of late-stage products is unlikely to deliver much this year. Amgen, the biggest of the major biotech firms, delivered solid results. First-quarter earnings increased 15% to $1.3 billion, based on sales of $3.7 billion, also up 15%. Several reliable performers in its portfolio helped boost growth; Neulasta and Neupogen, both to reduce the risk of a whiteblood-cell disorder in cancer patients, brought in combined sales of $1.0 billion, a 14% improvement, while sales of the arthritis treatment Enbrel totaled $730 million, up 11%. But during the quarter, these results were overshadowed by negative news con-
cerning several products in Amgen's portfolio AMGEN'S BIG DIP that could impact future Stock dropped in March over drug safety concerns growth. Sales of the anemia drug Aranesp, _^_______ Stock price, $ 80 perhaps the company's most important product, rose 15% to $1.0 billion, well below Wall Street expectations. Amgen said the lackluster performance was due to a backlog of inventory from the previous quarter and negative patient response to label 50 M M N D changes. 2007—2006— In March, Amgen added a black-box warning NOTE: From Nov. 13,2006, to May 11; tall ticks mark first business day of the week. to the labels of Aranesp and Epogen to indicate threshold and should be administered for that high doses of erythropoiesis-stimulatshorter periods. ing agents (ESAs) such as Aranesp, Epogen, "We may need another quarter or two and Johnson & Johnson's Procrit carry a to fully gauge the impact of the ESA safety high risk of serious, sometimes deadly, side concerns," says Morgan Stanley stock anaeffects in cancer patients. Cancer patients lyst Steven D. Harr. He trimmed his foreaccount for about 80% of U.S. sales of lllllllllllllllllllllllllllllllllMllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll
ONICHEM The Company Of Specialty Chemicals Organo-Functional Silanes Glyoxal 40% Glutaraldehyde 50% Onichem Specialities Co., Ltd. Tel: 86-411-84794022 Fax: 86-411-84794077 E-mail:
[email protected] Please visit www.onichem.com for the details
Meet us at Stand CS21, Chemspec/Chemsource 2007
www.CEN-ONLINE.ORG
2 6
MAY 21, 2007
cast for Aranesp in light of the uncertainty, although he slightly raised his expectations for Epogen, which has not come under such scrutiny. Sales of Epogen increased 3% in the quarter to $625 million. Amgen watchers are also rethinking the potential of a key new Amgen product, the cancer drug Vectibix. Even though Vectibix had been touted as a competitor for ImGlone System's Erbitux, sales have not picked up as quickly as analysts expected. Vectibix brought in $51 million in the quarter, compared with sales of $39 million in the fourth quarter of 2006. Furthermore, Amgen discontinued a study of Vectibix in March after an early analysis showed that adding the drug to a regimen that includes Genentech's Avastin and chemotherapy actually accelerated disease progression in colon cancer patients. Analysts are now wondering whether Erbitux, which targets the same receptor as Vectibix does, just works better. ImClone says sales of Erbitux rose 34% in the quarter to $306 million. It maybe too early to judge the merit of investing in expanded clinical trials for Vectibix after the results, Harr says, but "R&D resource allocation is becoming a larger issue, and Amgen may need to take a harder look at this development program at some point in the future." Other big biotech companies had less dramatic quarters. Biogen Idee, challenged by a mature product portfolio, offered steady results. First-quarter profits increased 7% to $202 million, based on revenues of $716 million, a 17% improvement. The multiple sclerosis treatment Avonex brought in $449 million, a 14% increase, and Biogen collected $207 million in revenues from Rituxan, the treatment for arthritis and non-Hodgkin's lymphoma that it comarkets with Genentech. Tysabri, the multiple sclerosis treatment that Biogen withdrew and then returned to the market last summer, is steadily making its way to patients. Worldwide sales of the drug totaled $48 million, of which Biogen brought home $30 million. Notably, Biogen and its U.S. marketing partner, Elan, reported no new cases of the rare brain disease, progressive multifocal leukoencephalopathy, that had led to the drug's withdrawal in early 2005. Biogen also made progress in the quarter toward refreshing its portfolio, which has grown stale in the past two years. The company began Phase III clinical trials for BG-12, an oral treatment for multiple
sclerosis, and galiximab, an anti-CD8o antibody for lymphoma. The firm also initiated a registration trial for lumiliximab, an anti-CD23 antibody for the treatment of chronic lymphocytic leukemia. However, these products are still several years away from the market. GENENTECH POSTED solid, though not exciting, first-quarter results. Product sales were healthy but no longer displayed the explosive growth witnessed in the past, and analysts are expecting little from the company's pipeline in the short term. Sales grew by a hefty 30% to $1.6 billion, and profits surged 61% to $792 million. Sales of the cancer drugs Herceptin and Tarceva were a little weaker than analysts had expected. Herceptin brought in $311 million, or a 7% increase over the first quarter of 2006. Tarceva sales totaled $102 million, a 10% increase from the year-ago quarter but down from $107 million in the fourth quarter of last year. Genentech and its partner OSI Therapeutics are running a host of trials across a range of cancers that, if they yield positive results, could boost
revenues as early as the fourth quarter. Lucentis, the eye disease therapy Genentech launched last summer, raked in $211 million. The drug is reported to have cornered just over half of new patients with wet age-related macular degeneration, while Genentech's slightly older cancer drug Avastin is the second choice among physicians, according to James Reddoch, a stock analyst with Friedman Billings Ramsey. Because Lucentis is a fragment of the antibody in Avastin, some doctors use the less expensive Avastin off-label to treat the eye disease. Avastin sales in the quarter totaled $533 million, a 34% increase. "We believe there are plenty of indications left for Avastin," Morgan Stanley's Harr says, noting potential use in breast, lung, ovarian, and prostate cancers. Reddoch points to Avastin's potential use as an adjuvant, to be given to cancer patients after surgery to keep any remaining cancer cells at bay. He believes such use in breast and colon cancers could add $1 billion to U.S. sales of the drug. However, he cautions, "the safety data need to be particularly clean." •
Continuing to Lead the way, innovating with
Quanta BioDesign, Ltd.
M o n o d i s p e r s e dPEG™s
NEW a n d NOVEL d P E G ™ D e s i g n s Azides and Trifunctionals with dPEG™s ! Try our Azides for Potential CLICK and STAUDINGER applications. USE our trifunctionals as NEW ways to incorporate the incredible properties of the dPEG™s
^ W ^ JC^)* x = 4,8,12
O
x = 4,8,12
Absolutely NfiW W$Y$ QftfomQ your cwpJfog titomtotinrWI O ^ ^m-dPEG8™ (dPEG4™-biotin) ^dPEG4™-Maleimide(Fmoc)
(HO) N H S H
... TWO introductory
trifunctionals!!
Q uantaBioDesign.com Fax Your Orders to ( 6 1 4 ) 7 6 0 - 9 7 8 1 or E-mail PO to
[email protected] WWW.CEN-0NLINE.ORG
27
MAY 2 1 , 2 0 0 7
